Moderna, Inc. (MRNA)
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Profit taking is hitting one of biotech's hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10% to $214.
Moderna: Best S&P 500 Stock YTD Could Rally Into YE, But Valuation Is Uncertain
Moderna has staged a dramatic rebound, becoming the best-performing S&P 500 stock YTD, driven by pipeline optimism and strong technical momentum. I maintain a "Hold" rating on MRNA due to persistent unprofitability, negative free cash flow, and a valuation highly dependent on pipeline execution. Key catalysts include upcoming Q3 earnings on November 6 and Analyst Day on November 12, with high implied volatility and significant event-driven price risk.
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Healthcare is drawing fresh buying as money moves away from the market's popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are up 6% to $239.
Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
Shares of Moderna MRNA have gained more than 5% over the past week, adding roughly $4.2 billion in market value.
Here's Why Moderna (MRNA) Fell More Than Broader Market
In the closing of the recent trading day, Moderna (MRNA) stood at $213.63, denoting a -5.05% move from the preceding trading day.
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect.
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure
Arbutus Biopharma is rated Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Imdusiran, ABUS's RNAi asset for chronic hepatitis B, targets a functional cure and could generate $1.59–$2.39B in peak annual revenue if successful. Current valuation ($4.50/share) slightly exceeds risk-adjusted fair value ($3.91), with upside tied to positive Phase 2b/3 Imdusiran results.
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.
Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
The healthcare sector stood out as one of the few bright spots in Wednesday's trading.
Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?
Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run now raises a hard question about what comes next. Moderna stock is up 545% year-to-date to $190.
